Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Stankoff

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|March 31, 2022
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic ModelsMichael Dietrich, Christina Hecker, Elodie Martin, et al.
Research Square|November 24, 2025
Network-based disease fingerprinting with neuroinflammation PET imagingLeonardo Barzon, Lucia Maccioni, Michelle Carranza Mellana, et al.
Journal of Neuroinflammation|April 9, 2026
Network-based disease fingerprinting with neuroinflammation PET imagingLeonardo Barzon, Lucia Maccioni, Michelle Carranza Mellana, et al.
Nature Reviews. Neurology|January 15, 2025
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMTPaolo A Muraro, Alice Mariottini, Raffaella Greco, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2024
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022Lina Jeantin, Edouard Januel, Pierre Labauge, et al.
Frontiers in Neurology|January 2, 2023
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapiesEli Hatchwell, Edward B Smith, Shapour Jalilzadeh, et al.
Annals of Clinical and Translational Neurology|July 9, 2021
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and FranceMaria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
JAMA Neurology|February 26, 2014
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective studyMikael Cohen, Elisabeth Maillart, Ayman Tourbah, et al.
JAMA Neurology|February 12, 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisNail Benallegue, Fabien Rollot, Sandrine Wiertlewski, et al.
Nature Medicine|July 9, 2026
Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteriaJiwon Oh, Frederik Barkhof, Amit Bar-Or, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
Neurology(R) Neuroimmunology & Neuroinflammation|March 31, 2022
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic ModelsMichael Dietrich, Christina Hecker, Elodie Martin, et al.
Research Square|November 24, 2025
Network-based disease fingerprinting with neuroinflammation PET imagingLeonardo Barzon, Lucia Maccioni, Michelle Carranza Mellana, et al.
Journal of Neuroinflammation|April 9, 2026
Network-based disease fingerprinting with neuroinflammation PET imagingLeonardo Barzon, Lucia Maccioni, Michelle Carranza Mellana, et al.
Nature Reviews. Neurology|January 15, 2025
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMTPaolo A Muraro, Alice Mariottini, Raffaella Greco, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2024
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022Lina Jeantin, Edouard Januel, Pierre Labauge, et al.
Frontiers in Neurology|January 2, 2023
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapiesEli Hatchwell, Edward B Smith, Shapour Jalilzadeh, et al.
Annals of Clinical and Translational Neurology|July 9, 2021
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and FranceMaria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
JAMA Neurology|February 26, 2014
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective studyMikael Cohen, Elisabeth Maillart, Ayman Tourbah, et al.
JAMA Neurology|February 12, 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisNail Benallegue, Fabien Rollot, Sandrine Wiertlewski, et al.
Nature Medicine|July 9, 2026
Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteriaJiwon Oh, Frederik Barkhof, Amit Bar-Or, et al.
Pageof 16